Australia markets close in 2 hours 31 minutes
  • ALL ORDS

    7,540.70
    -11.40 (-0.15%)
     
  • ASX 200

    7,277.00
    -21.50 (-0.29%)
     
  • AUD/USD

    0.7576
    -0.0000 (-0.00%)
     
  • OIL

    73.17
    +0.09 (+0.12%)
     
  • GOLD

    1,775.50
    -7.90 (-0.44%)
     
  • BTC-AUD

    43,230.88
    -1,778.52 (-3.95%)
     
  • CMC Crypto 200

    789.65
    -20.54 (-2.54%)
     
  • AUD/EUR

    0.6352
    +0.0004 (+0.07%)
     
  • AUD/NZD

    1.0740
    -0.0002 (-0.02%)
     
  • NZX 50

    12,551.95
    -34.54 (-0.27%)
     
  • NASDAQ

    14,274.24
    +3.83 (+0.03%)
     
  • FTSE

    7,074.06
    -15.95 (-0.22%)
     
  • Dow Jones

    33,874.24
    -71.34 (-0.21%)
     
  • DAX

    15,456.39
    -179.94 (-1.15%)
     
  • Hang Seng

    28,785.34
    -31.73 (-0.11%)
     
  • NIKKEI 225

    28,920.12
    +45.23 (+0.16%)
     

C4 Therapeutics to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET

  • Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.

About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting